Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat DDI study in B-cell lymphoma and solid tumors
NCT03028103Phase 1Completed
- Sponsor
- Epizyme, Inc.
- Start
- Mar 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tazemetostat in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL) and 3 more (2 arms), sponsored by Epizyme, Inc. Primary endpoints: Area Under the Curve and Maximum Plasma Concentration. Started Mar 2017; status: completed.
02
Drugs
tazemetostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03028103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03028103.